The Woodford effect: Teetering on the edge, his co-investors are feeling the pain — and they want it to stop

John Carroll

Editor & Founder

Neil Woodford’s woes have a ripple effect that is spreading the pain. And that’s made him an unwelcome investor at the biotechs he’s backed on both sides of the Atlantic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

view job offer post your job now

TRENDING NOW

The Woodford effect: Teetering on the edge, his co-investors are feeling the pain — and they want it to stop

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa

The Wood­ford ef­fect: Tee­ter­ing on the edge, his co-in­vestors are feel­ing the pain — and they want it to stop

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

more like this

Benchling

San Francisco, CA, USA

The Woodford effect: Teetering on the edge, his co-investors are feeling the pain — and they want it to stop